



# Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

2026-05-27

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET.

A live webcast can be accessed in the Investors section of the Silence website at [www.silence-therapeutics.com](http://www.silence-therapeutics.com). An archived replay of the webcast will be available following the conference.

## About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit <https://www.silence-therapeutics.com/>.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20260527647991/en/>

Inquiries:

Silence Therapeutics plc

Gem Hopkins, VP, Head of IR and Corporate Communications

[ir@silence-therapeutics.com](mailto:ir@silence-therapeutics.com)

Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc